{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:52:19Z","timestamp":1791910339788,"version":"4.3.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Backgrounds and Aims:<\/jats:title>\n                    <jats:p>Chronic hepatitis C (CHC) infection can leads to chronic liver disease, fibrosis, then cirrhosis, and, finally, hepatocellular carcinoma (HCC); moreover, it is the most common indication for liver transplantation. Liver biopsy is still the gold standard method for the staging of liver fibrosis as it is an invasive procedure with complications. There are some noninvasive methods such as fibroscan that are now the investigation of choice; FIB-4 and aminotransferase to platelet ratio index (APRI) are other noninvasive tools to assess liver fibrosis by using aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, and age. This study aims to evaluate the efficacy and performance of FIB-4 and APRI against fibroscan in patients infected with the hepatitis C virus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>It is a cross-sectional study that was conducted in a tertiary health care center in Uttar Pradesh, India, from January 2017 to January 2020. Fibroscan was done for all patients. A blood sample was used to determine AST, ALT, and platelet count. FIB-4 and APRI were calculated from laboratory data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>187 of the 487 patients in the study have F0-F1 fibrosis, 69 have F2, 53 have F3 fibrosis, and 178 have cirrhosis. Based on receiver operating characteristic (ROC) analysis, single optimum cut-offs for diagnosing significant fibrosis and cirrhosis were 1.2 for APRI and 2.25 for FIB-4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Compared with Fibroscan, APRI and FIB-4 showed good performance in detecting the patients without liver fibrosis as well as satisfactory performance in detecting significant fibrosis. These scores should be used in combination with other noninvasive scores for an accurate assessment of liver fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_666_21","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T06:06:24Z","timestamp":1638425184000},"page":"4082-4088","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":39,"title":["APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection"],"prefix":"10.4103","volume":"10","author":[{"given":"Sumit","family":"Rungta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Deep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlendra","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchit","family":"Swaroop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20240828","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection:New estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"R2-23-20240828","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1186\/s12879-017-2722-0","article-title":"Future complications of chronic hepatitis C in a low-risk area:Projections from the hepatitis c study in Northern Norway","volume":"17","author":"Kileng","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R4-23-20240828","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/gut.36.3.437","article-title":"Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales:An audit by the British Society of Gastroenterology and the Royal College of Physicians of London","volume":"36","author":"Gilmore","year":"1995","journal-title":"Gut"},{"key":"R5-23-20240828","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.22748","article-title":"Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C","volume":"49","author":"Lucidarme","year":"2009","journal-title":"Hepatology"},{"key":"R6-23-20240828","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"R7-23-20240828","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis:An updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"R8-23-20240828","doi-asserted-by":"crossref","first-page":"595602","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"Soderberg","year":"2010","journal-title":"Hepatology"},{"key":"R9-23-20240828","doi-asserted-by":"crossref","first-page":"200523","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease:practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"R10-23-20240828","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0301-5629(02)00489-1","article-title":"Elastic modulus measurements of human liver and correlation with pathology","volume":"28","author":"Yeh","year":"2002","journal-title":"Ultrasound Med Biol"},{"key":"R11-23-20240828","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","article-title":"Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients","volume":"30","author":"Kim","year":"2010","journal-title":"Liver Int"},{"key":"R12-23-20240828","doi-asserted-by":"crossref","first-page":"e0164883","DOI":"10.1371\/journal.pone.0164883","article-title":"Diagnostic accuracy of the enhanced liver fibrosis (ELF\u00ae) score using hcv-infected serum samples cryopreserved for up to 25 years","volume":"11","author":"Puigveh\u00ed","year":"2016","journal-title":"PLoS One"},{"key":"R13-23-20240828","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4:An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"R14-23-20240828","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/cid\/ciu939","article-title":"Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus","volume":"60","author":"Berenguer","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R15-23-20240828","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3855\/jidc.10190","article-title":"FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C \u2013A developing country's perspective in DAA era","volume":"12","author":"Karic","year":"2018","journal-title":"J Infect Dev Ctries"},{"key":"R16-23-20240828","first-page":"110","article-title":"Diagnostic performances of APRI and FIB-4 score for the evaluation of liver fibrosis in patients with chronic hepatitis C","volume":"17","author":"Daniela","year":"2013","journal-title":"Ther Pharmacol Clin Toxicol"},{"key":"R17-23-20240828","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"R18-23-20240828","doi-asserted-by":"crossref","first-page":"e0199760","DOI":"10.1371\/journal.pone.0199760","article-title":"APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level","volume":"13","author":"Yen","year":"2018","journal-title":"PLoS One"},{"key":"R19-23-20240828","first-page":"548","article-title":"A new scoring system for prediction of fibrosis in chronic hepatitis C","volume":"11","author":"Bota","year":"2011","journal-title":"Hepat Mon"},{"key":"R20-23-20240828","first-page":"103","article-title":"Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI):Usefulness in patients with chronic liver disease:APRI in chronic liver disease","volume":"11","author":"Yilmaz","year":"2011","journal-title":"Hepat Mon"},{"key":"R21-23-20240828","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1665-2681(19)31807-1","article-title":"Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C","volume":"8","author":"Borsoi Viana","year":"2009","journal-title":"Ann Hepatol"},{"key":"R22-23-20240828","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3109\/00365521.2011.574725","article-title":"Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients","volume":"46","author":"Stibbe","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"R23-23-20240828","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-230X-11-91","article-title":"Non-invasive markers for hepatic fibrosis","volume":"11","author":"Baranova","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"R24-23-20240828","first-page":"498","article-title":"Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography","volume":"32","author":"Papadopoulos","year":"2019","journal-title":"Ann Gastroenterol"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_666_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:16:03Z","timestamp":1787166963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_666_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_666_21","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}